{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"argenx SE"},"Symbol":{"label":"Symbol","value":"ARGX"},"Address":{"label":"Address","value":"WILLEMSTRAAT 5, BREDA, 4811 AH, Netherlands"},"Phone":{"label":"Phone","value":"+31 763030488"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland."},"CompanyUrl":{"label":"Company Url","value":"https://www.argenx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Filip Borgions","title":"Global Head-Technical Operations"},{"name":"Karen Massey","title":"Chief Operating Officer"},{"name":"Luc Truyen","title":"Chief Medical Officer"},{"name":"Peter Ulrichts","title":"Chief Scientific Officer"},{"name":"Tim van Hauwermeiren","title":"Chief Executive Officer & Executive Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}